EW — Edwards Lifesciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $51.73bn
- $50.75bn
- $6.00bn
- 90
- 16
- 81
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 1,047 | 823 | 1,503 | 1,522 | 1,399 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 235 | 131 | -9.7 | 233 | 150 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -204 | 42.2 | 145 | -421 | -526 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 1,179 | 1,054 | 1,732 | 1,218 | 896 |
Capital Expenditures | -278 | -407 | -330 | -265 | -266 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -317 | -124 | -1,393 | 517 | 440 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -596 | -531 | -1,723 | 252 | 174 |
Financing Cash Flow Items | -2.8 | -1.2 | -0.3 | -3.6 | -1 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -116 | -487 | -356 | -1,585 | -711 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 465 | 15.8 | -333 | -94.8 | 375 |